Trial Profile
A PROSPECTIVE, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY & EFFICACY OF ANIDULAFUNGIN WHEN USED TO TREAT CHILDREN WITH INVASIVE CANDIDIASIS, INCLUDING CANDIDEMIA
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Anidulafungin (Primary) ; Fluconazole
- Indications Candidaemia; Invasive candidiasis
- Focus Adverse reactions; Registrational
- Sponsors Pfizer
- 19 Mar 2020 Results (N=163) pharmacokinetic of Anidulafungin in pooled population analysis from 4 studies, published in the Clinical Pharmacology and Therapeutics
- 06 Feb 2020 Results (n=19) published in the Pediatric Infectious Disease Journal.
- 16 Apr 2019 Results presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases